Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin plus lifestyle intervention in prediabetes
2024-512179-11-00Phase 4Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in prediabetes comparing Dapagliflozin + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Primary endpoint: Frequency of remission of hyperglycemia at end of treatment. Planned start Oct 2023; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
prediabetes
Beyond the preview
Go deeper on 2024-512179-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512179-11-00.